TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00712803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN3-3'D4delta30
Description: Live attenuated 10\^3 dose of rDEN3-3'D4delta30 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN3-3'D4delta30
Description: Live attenuated 10\^5 dose of rDEN3-3'D4delta30 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN3-3'D4delta30
Description: Live attenuated 10\^1 dose of rDEN3-3'D4delta30 vaccine.
Study: NCT01676623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard government health services
Description: This intervention will be basic preventive and curative health services provided by the commune health centers. This includes antenatal care, postnatal care and basic nutrition related counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard government health services
Description: This intervention will be basic preventive and curative health services provided by the commune health centers. This includes antenatal care, postnatal care and basic nutrition related counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alive & Thrive IYCF franchise services
Description: This intervention includes intensive behavioral counseling to improve infant and young child feeding. A package of 15 counseling contacts that are quality assured and branded will be offered to families of infants and young children. Services might also include user fees.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mass media campaign
Description: Alive \& Thrive is implementing a nationwide mass media campaign in 2011, 2012 and 2013, with a focus on improving breastfeeding practices. The mass media intervention includes TV and radio spots as well as an internet site and a telephone hotline.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mass media campaign
Description: Alive \& Thrive is implementing a nationwide mass media campaign in 2011, 2012 and 2013, with a focus on improving breastfeeding practices. The mass media intervention includes TV and radio spots as well as an internet site and a telephone hotline.
Study: NCT03493984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginger exosomes
Description: Naturally occurring plant exosomes from ginger

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginger exosomes
Description: Naturally occurring plant exosomes from ginger

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aloe exosomes
Description: Naturally occurring plant exosomes from aloe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aloe exosomes
Description: Naturally occurring plant exosomes from aloe

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Exosome placebo tablet
Study: NCT00352521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Study: NCT00488904

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supportan
Description: 2 sip feed pr. day
Study: NCT00352521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Study: NCT06240156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D arch pad design Insole group
Description: 3D three-dimensional design that is already available on the market (patent number I315187). Its arch support principle is designed using 3DBS (Three-Dimensional Biomechanics System - 3DBS), which can conform to the user's feet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: flat Insole group
Description: General Insole without any special features
Study: NCT02423538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: Oral tablets (1 mg, 5 mg, 10 mg)
Study: NCT00488904

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: supportan placebo
Description: 2 sip feed pr. day
Study: NCT02483949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus
Study: NCT04494308

Intervention type: OTHER
Intervention: biomarker identification
Description: flow cytometric analysis of eosinophils membrane molecules

Intervention type: OTHER
Intervention: biomarker identification
Description: flow cytometric analysis of eosinophils membrane molecules
Study: NCT02423538

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR0302 placebo comparator
Description: Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
Study: NCT04956588

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: surgical robot
Description: The surgical robot completed the screw placement according to the surgical plan, and the researchers closely monitored the screw placement process.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: controlled approach
Description: The screw placement was performed using a controlled approach according to the surgical plan.
Study: NCT03972956

Intervention type: OTHER
Intervention: No intervention will be given to patients.
Description: Samples are collected at the time of a scheduled surgery that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.

Intervention type: OTHER
Intervention: No intervention will be given to patients.
Description: Samples are collected at the time of a scheduled surgery that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
Study: NCT03251950

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: healthy eating and gardening
Description: 15 week healthy eating and gardening intervention for children aged 3-5 years; 15 week online parenting intervention to promote healthy eating; Menu change in early childhood center to promote healthy eating

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: healthy eating and gardening
Description: 15 week healthy eating and gardening intervention for children aged 3-5 years; 15 week online parenting intervention to promote healthy eating; Menu change in early childhood center to promote healthy eating
Study: NCT03323866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 0.5 MG/ML
Description: 2 cc nebule of budesonide in 240 cc of saline water (Sinus Rinse) once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone nasal spray
Description: Mometasone 50 mcg/spray 2 sprays twice daily
Study: NCT03842072

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical collar
Description: cervical collars prescribed will be use immediately following anterior cervical discectomy and fusion surgery.
Study: NCT03137693

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Schedule Variation: SABR
Description: SABR will be delivered over 3 days, prior to surgery.
Study: NCT03220854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological: humanized anti-PD-L1 monoclonal antibody
Description: Standard of Care - patient will continue to be given the same PD-L1 inhibitor they were receiving prior to study registration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological: humanized anti-PD-L1 monoclonal antibody
Description: Standard of Care - patient will continue to be given the same PD-L1 inhibitor they were receiving prior to study registration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological: humanized anti-PD-L1 monoclonal antibody
Description: Standard of Care - patient will continue to be given the same PD-L1 inhibitor they were receiving prior to study registration
Study: NCT00429429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Description: Drops of peanut protein placed and held under the tongue for a specific time before swallowed.
Study: NCT00788541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 60 mg/ML
Description: Administered as an injection into an anterior juxtascleral depot

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anecortave Acetate Vehicle
Description: Administered as an injection into an anterior juxtascleral depot

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anecortave Acetate Vehicle
Description: Administered as an injection into an anterior juxtascleral depot
Study: NCT02430259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly INH / RRT given by DOT
Description: weekly oral Rifapentine 15 mg/kg (up to 900mg) plus Isoniazid 15 mg/kg (up to 900mg) for 12 doses
Study: NCT06075641

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gingival depigmentation
Description: Gingival depigmentation is the most widely used periodontal procedure to remove or reduce the melanotic areas. Various techniques can be employed to effectively carry out the depigmentation procedure, including surgical scraping, scalpel technique, bur abrasion, free gingival graft, gingivectomy, cryosurgery, electrosurgery, chemical therapies, and different types of lasers

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gingival depigmentation
Description: Gingival depigmentation is the most widely used periodontal procedure to remove or reduce the melanotic areas. Various techniques can be employed to effectively carry out the depigmentation procedure, including surgical scraping, scalpel technique, bur abrasion, free gingival graft, gingivectomy, cryosurgery, electrosurgery, chemical therapies, and different types of lasers
Study: NCT01724905

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified Stop Light Diet (SLDm)
Description: SLDm includes reduced energy pre-packaged meals (PM) for 6 months, encouraged consumption of low energy shakes and 35 fruits and vegetables (F/V) per week

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Recommended Care Diet
Description: RC diet includes traditional meal plans and 35 fruits and vegetables per week
Study: NCT00199524

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navigator Ureteral Access Sheath
Description: ureteral access sheath
Study: NCT00853099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: adalimumab
Study: NCT00578630

Intervention type: OTHER
Intervention: buccal swabs and obtaining peripheral blood
Description: will be the collection of normal cells and assessments of toxicity following chemotherapy at routine clinic visits.
Study: NCT01362387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternative follow-up protocol
Description: Women (n=1000) will be allocated by chance to one of two groups: alternative follow-up using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test, or standard follow-up which consists of an in person visit with an ultrasound or a telephone call and high sensitivity pregnancy test.
Study: NCT00437255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Propionate, 0.05%
Description: Topical, twice daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriene and betamethasone dipropionate ointment
Description: Topical, once daily
Study: NCT04199143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide-Oxygen
Description: The medical product used in this study is a gas for common medical use in various domains including anesthesic, consisting in the equimolar mixture of nitrous oxide and oxygen. Subjects will receive a mixture of 50% N2O / 50% O2 for 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide-Oxygen
Description: The medical product used in this study is a gas for common medical use in various domains including anesthesic, consisting in the equimolar mixture of nitrous oxide and oxygen. Subjects will receive a mixture of 50% N2O / 50% O2 for 1 hour.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Pulsatility Imaging - TPI
Description: Tissue Pulsatility Imaging (TPI) is a variation of ultrasonic Doppler strain imaging we are developing to measure the local expansion and relaxation of the brain tissue over the cardiac cycle to characterize and image perfusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Pulsatility Imaging - TPI
Description: Tissue Pulsatility Imaging (TPI) is a variation of ultrasonic Doppler strain imaging we are developing to measure the local expansion and relaxation of the brain tissue over the cardiac cycle to characterize and image perfusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging - MRI
Description: Structural and Functionnal (including BOLD and ASL) MRI will be aquired in this study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging - MRI
Description: Structural and Functionnal (including BOLD and ASL) MRI will be aquired in this study
Study: NCT03079856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Intervention for emerging adults (EAs) seeking care in the ED. The intervention will be rooted in motivational interviewing (MI) and will be guided by social cognitive, self-determination, and the trans-theoretical theories. The ED visit presents a teachable moment for intervening to promote health behavior, therefore eligible EAs will receive a \~30 minute MI-based session in the ED. In order to capitalize on and potentially extend this moment, participants will receive daily booster notifications delivered through a secure mobile app that they will download to their phone at enrollment.
Study: NCT02174146

Intervention type: PROCEDURE
Group type: OTHER
Intervention: non-surgical periodontal therapy
Description: supra and subgingival debridement
Study: NCT01722656

Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept
Study: NCT04397328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine vs placebo (1:1 design) double blind intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hydroxychloroquine vs placebo (1:1 design) double blind intervention
Study: NCT00326248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW679769 (casopitant)
Study: NCT02193113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD001 Injection
Description: A novel plasma kallikrein inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD001 Injection
Description: A novel plasma kallikrein inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD001 Injection
Description: A novel plasma kallikrein inhibitor
Study: NCT03927404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active vacuum test prosthesis
Description: The adaptive vacuum prosthesis is sold as a commercial device by the company Willow Wood with suggested U.S. L-Code L5781. The device is designated as a Class 1 Medical Device and 510(K) Exempt. This category is part of a low or moderate risk to patient safety and health. The Prosthetic socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
Study: NCT01608841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 100 mg 1# PO qd till disease progression
Study: NCT05685056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Texts with detailed information focusing on nutrition and iodine rich foods specifically, every 3-5 days.
Study: NCT02641067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally
Study: NCT04659694

Intervention type: OTHER
Group type: OTHER
Intervention: Wellness programme provided by Oomph! Wellness company
Description: The Oomph! wellness programme empowers older adults to lead a full life for life. It focuses on building an individual-centred programme that consists of a varied exercise and activity plans including days out. All of these, aims in improving the physical and psychosocial wellness in older adults. This intervention is a three day training session for care home staff to understand and learn how to facilitate care activities within their care home.
Study: NCT02186704

Intervention type: DEVICE
Intervention: ICD with DX system
Description: Implantable cardioverter defibrillator (ICD) system implantation with single lead with ventricular sensing and pacing and defibrillation combined with dedicated atrial sensing dipole.
Study: NCT02342262

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EcologicBarrier
Description: multispecies probiotic product, 2x10-9 cfu/gram

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: similar appearance as the probiotic product, but without bacteria
Study: NCT00498121

Intervention type: DEVICE
Intervention: PROCALCITONIN LEVEL
Description: measuring PROCALCITONIN LEVEL
Study: NCT03628274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) 7 Tesla
Description: An MRI performed as part of the project

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) 1,5 Tesla
Description: An MRI performed as part of the care
Study: NCT03189901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular management+Levosimendan
Description: Patients are treated with regular management recommended in guidelines and levosimendan.
Study: NCT01654809

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: evaluated vaccine
Description: 0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: evaluated vaccine
Description: 0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: evaluated vaccine
Description: 0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: imported compared vaccine
Description: 0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: imported compared vaccine
Description: 0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: imported compared vaccine
Description: 0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: domestic compared vaccine
Description: 0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: domestic compared vaccine
Description: 0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: domestic compared vaccine
Description: 0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
Study: NCT02874027

Intervention type: OTHER
Intervention: The TBI patients with depression
Description: The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.

Intervention type: OTHER
Intervention: The TBI patients with depression
Description: The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.
Study: NCT01147848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/Vilanterol Inhalation Powder
Description: Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate/salmeterol Inhalation Powder
Description: Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (1)
Description: Inhalation powder inhaled orally once daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (2)
Description: Inhalation powder inhaled orally twice daily for 24 weeks
Study: NCT00685737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1-MNA
Description: Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1-MNA
Description: Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study: NCT00259207

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary valve insertion
Description: Pulmonary valve insertion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: medical surgery hybride
Description: medical surgery hybride
Study: NCT03442660

Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional diagnostic or treatment procedures will be required. Subjects will be asked to complete electronic (or on paper when it's not possible to use electronic version) questionnaires.
Study: NCT01424280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1440115
Description: Single dose of either 750 mg or 500 mg administered as 250 mg tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of matching placebo tablets
Study: NCT00565799

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Omentectomy
Description: Removing the omentum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: Only LAGB without Omentectomy